Categories: News

Clarivate delivers new AI-powered solutions within Innography for competitive benchmarking and standard-essential patent analysis

AI Classifier delivers patent classification with up to 97% first-pass accuracy for portfolio benchmarking, while SEP Analyzer enhances reporting with clear, intuitive visualizations

- Advertisement -

LONDON, Oct. 1, 2025 /PRNewswire/ — Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of two new solutions for Innography customers: Innography AI Classifier for portfolio benchmarking, and Innography SEP Analyzer for streamlining standard essential patent (SEP) negotiations. These enhancements continue to expand on Innography’s legacy of aligning patents with business strategy, empowering faster and more confident patent portfolio, licensing and commercialization decisions.

- Advertisement -

Innography AI Classifier leverages AI technology powered by supervised machine learning and large language models (LLMs), utilizing Derwent World Patents Index data, for highly precise classification that is up to 97% accurate the very first time. Through this powerful technology, patent professionals can categorize patents on a large and repeatable scale, using a customized lens to view their own portfolio or competitors’ portfolios. It may be leveraged with or without training data and can condense a classification job from weeks to minutes. AI Classifier accelerates organizations’ portfolio strategy decisions.

- Advertisement -

Innography SEP Analyzer streamlines research by normalizing and categorizing standard essential patent data and provides visualizations to clearly summarize and report results. Through the tool, patent strategists and licensing professionals can gain objective declaration insights into competitor portfolios to accelerate licensing negotiations.

- Advertisement -

Shandon Quinn, Vice President, Patent Intelligence, Clarivate, said: “Innography SEP Analyzer is another example of Clarivate offering its best-in-class data through solutions that support critical decisions. Together with the AI Classifier, these new capabilities in Innography represent an important step forward in leveraging AI technology and enriched data to drive patent portfolio strategies and commercial decisions.”

- Advertisement -

To learn more, please visit Innography AI Classifier and Innography SEP Analyzer.

- Advertisement -

About Clarivate

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

- Advertisement -

Media contact:
Sofia Nogués, Sr. External Communications Manager
newsroom@clarivate.com 

- Advertisement -

Logo – https://mma.prnewswire.com/media/1159266/Clarivate_Logo_v1.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/clarivate-delivers-new-ai-powered-solutions-within-innography-for-competitive-benchmarking-and-standard-essential-patent-analysis-302571935.html

- Advertisement -

Recent Posts

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast,…

7 hours ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

10 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

10 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

11 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

11 hours ago